You are here: Industry Insights > ASH

News List

InnoCare to Present Orelabrutinib Data at the Upcoming 63rd Annual Meeting of ASH prnasia
November 09, 2021
InnoCare Pharma (HKEX: 09969), a leading biotech company, announced today that the company will present latest data of its BTK inhibitor orelabrutinib at the 63rd American Society of Hematology (ASH)...
ASH Suggests Not Using Outpatient Thromboprophylaxis for COVID-19 drugs
July 20, 2021
A new draft recommendation relating to anticoagulation for discharged patients with COVID-19 has been issued by the American Society of Hematology (ASH).
Off-the-shelf cell therapy for cancer? Fate Therapeutics to make its case at ASH fiercebiotech
January 03, 2019
Shares of cell therapy developer Fate Therapeutics shot up more than 8% Friday morning to $15.31 after the company announced that the FDA accepted its IND application for a ......
Pfizer's biosimilar proves non-inferior to rituximab in lymphoma at ASH 2018 pharmafile
December 07, 2018
Joining the chorus of data presentations at the American Society of Hematology (ASH) Annual Meeting 2018, Pfizer has announced new data for its biosimilar version of Genentech’s
Hemlibra shows "clinically meaningful" bleed control in paediatric haemophilia A patients pharmafile
December 07, 2018
In another reveal at the American Society of Hematology (ASH) Annual Meeting 2018, Roche unveiled new Phase 3 findings for Hemlibra (emicizumab) as a prophylactic in haemophilia A patients
Amgen unveils double whammy of data for its investigational cancer immunotherapies at ASH 2018 pharmafile
December 07, 2018
Amgen has presented the first clinical data at the American Society of Hematology (ASH) Annual Meeting 2018 for two investigational novel bispecific T cell engager (BiTE) immunotherapies...
Novartis unveils strong longer-term Kymriah data at ASH 2018 pharmafile
December 04, 2018
Novartis has lifted the curtain on longer-term analysis data for its CAR-T therapy Kymriah (tisagenlecleucel) at the American Society of Hematology (ASH) Annual Meeting 2018, showing that the treatment demonstrated
AbbVie's Venclyxto combo beats standard of care in chronic lymphocytic leukaemia pharmafile
December 04, 2018
AbbVie has taken the opportunity at the American Society of Hematology (ASH) Annual Meeting 2018 to reveal new data on venetoclax (Venclyxto) in combination with rituximab (VenR), in which it demonstrated
Gilead's CAR-T therapy Yescarta shows two-year response duration in large B-cell lymphoma pharmafile
December 04, 2018
Gilead has gone head to head with Novartis at the American Society of Hematology (ASH) Annual Meeting 2018, meeting the latter’s reveal of data on rival Kymriah with study findings of its own CAR-T therapy Yescarta (Axicabtagene Ciloleucel).
Spark Therapeutics Announces Updated Data on SPK-8011 from Ongoing Phase 1/2 Dose-escalation Clinical Trial in Hemophilia A at 60th American Society of Hematology (ASH) Annual Meeting and Exposition firstwordpharma
December 03, 2018
Among the five participants treated in the 2x1012 vg/kg cohort who did not experience an immune response-associated decline in FVIII expression, beginning four weeks after vector infusion, there has been a 100-percent reduction in bleeds and a greater tha

Previous page 1 2 Next page